Fredun Pharmaceuticals moves up on launching cellular longevity dedicated platform 'Daulcel'
Fredun Pharmaceuticals is currently trading at Rs. 2380.00, up by 13.55 points or 0.57% from its previous closing of Rs. 2366.45 on the BSE.
The scrip opened at Rs. 2370.00 and has touched a high and low of Rs. 2414.00 and Rs. 2361.05 respectively. So far 4019 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 2550.00 on 11-May-2026 and a 52 week low of Rs. 682.25 on 16-May-2025.
Last one week high and low of the scrip stood at Rs. 2550.00 and Rs. 2164.95 respectively. The current market cap of the company is Rs. 1309.26 crore.
The promoters holding in the company stood at 44.17%, while Institutions and Non-Institutions held 3.89% and 51.94% respectively.
Fredun Pharmaceuticals has launched ‘DAULCEL’, its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks another strategic step in its expansion into innovation-led and future-focused healthcare segments.
DAULCEL is positioned as a premium wellness platform centered on quality, innovation, and evolving consumer wellness needs. The brand is aimed at addressing the increasing global focus on vitality, wellness optimization, recovery-focused healthcare, and long-term healthy living through science-oriented wellness solutions.
